Search
Close this search box.

Press release: Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

  • Lonza to acquire Synaffix B.V., an innovative biotech company focused on antibody-drug conjugates (ADCs)
  • Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
  • Lonza and Synaffix will continue to expand their Center of Excellence for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies for cytotoxic ADCs, targeted gene therapy, immune cell engagers applications and beyond
  • The acquisition comprises an initial financial consideration of €100 million in cash and up to €60 million in additional performance-based consideration
 

Basel, Switzerland, and Amsterdam, Netherlands, 1 June 2023 – Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, today announced it has acquired Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage technology platform for the development of ADCs. Synaffix revenues and margins will be recognized within the Lonza business from the date of acquisition.

While ADCs offer widespread and targeted treatment potential against cancer, they present a range of complex development and manufacturing challenges. Supported by a team of scientific experts, the Synaffix technology platform, which includes payload and site-specific linker technologies, will enhance and extend Lonza’s integrated ADC services, including its early-phase offering. The award-winning Synaffix ADC technology platform comprises proprietary GlycoConnect™, HydraSpace™ and toxSYN™ technologies that can considerably enhance the efficacy and tolerability of ADCs.

Combining Lonza’s development and manufacturing capabilities with the Synaffix ADC technology platform will provide customers and licensees with a comprehensive service to rapidly discover, develop, scale up and commercialize novel and differentiated ADCs. These enhanced capabilities will streamline the path to clinic and commercialization.

Ulrich Osswald, Vice President, Licensing, Lonza, commented: “The Synaffix ADC technology is the gold standard, helping clinical-stage developers to design potentially curative therapies in areas of high unmet medical need. The acquisition of Synaffix underlines the strategic position of bioconjugates within Lonza’s portfolio, expands our offering in this fast-growing market and enhances our value proposition for clinical customers. With Synaffix, our combined industry-leading knowledge and capabilities have the capacity to support both clinical and commercial needs.”

Peter van de Sande, CEO, Synaffix, added: “On our mission to bring Synaffix’s ADC technologies to patients, we are excited to become part of Lonza and thus, through strong and immediate synergies, ensure a robust technology and manufacturing platform for our licensees as they progress into the late stage clinical and commercial development phase. We can now also leverage the potential offered by Lonza to fast-track technology innovations in bioconjugates beyond cytotoxic ADCs. We look forward to working closely with our colleagues at Lonza for the continued enablement of promising potential medicines for patients in need.”

As a Lonza company, Synaffix will continue to operate under the Synaffix name and further expand its operations in Oss (NL) to cater for further innovation and growth.

The acquisition reflects Lonza’s strategy to differentiate through technology and innovation. From its leading bioconjugation offering, to the commercial manufacture of cell and gene therapies and support in producing live biotherapeutics, Lonza’s manufacturing technologies help customers deliver innovative new therapies to patients.

Bird & Bird acted as legal advisor to Lonza. William Blair acted as financial advisor and Goodwin and NautaDutilh acted as legal advisors to Synaffix. 

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.